期刊
PHARMACEUTICAL STATISTICS
卷 16, 期 2, 页码 100-106出版社
WILEY
DOI: 10.1002/pst.1801
关键词
combined approvals; first-in-human; healthy volunteer; protocol; recommendations; study design
资金
- European Union's FP7 programme [602552]
- MRC [MC_U105260794] Funding Source: UKRI
- Medical Research Council [MC_U105260794] Funding Source: researchfish
By setting the regulatory-approved protocol for a suite of first-in-human studies on BIA 10-2474 against the subsequent French investigations, we highlight 6 key design and statistical issues, which reinforce recommendations by a Royal Statistical Society Working Party, which were made in the aftermath of cytokine release storm in 6 healthy volunteers in the United Kingdom in 2006. The 6 issues are dose determination, availability of pharmacokinetic results, dosing interval, stopping rules, appraisal by safety committee, and clear algorithm required if combining approvals for single and multiple ascending dose studies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据